| Drug Name |
Vinorelbine tartrate |
| Drug ID |
BADD_D02364 |
| Description |
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) [L1998]. It was initially approved in the USA in 1990's for the treatment of NSCLC [L2010].
It is a third-generation vinca alkaloid. The introduction of third-generation drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with very similar results from the various drugs. Treatment toxicities are considerable in the combination treatment setting [A32347].
A study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear mutations. It was found that there was 4.3-fold variation in vinorelbine clearance across the cohort, suggesting a strong influence of genetics on the clearance of this drug [L2002]. |
| Indications and Usage |
Not Available |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
L01CA04 |
| DrugBank ID |
DB00361
|
| KEGG ID |
D01935
|
| MeSH ID |
D000077235
|
| PubChem ID |
16051941
|
| TTD Drug ID |
D01HTL
|
| NDC Product Code |
66529-0012; 66529-0001; 69910-0004; 62158-0001 |
| Synonyms |
Vinorelbine | 5'-Nor-anhydrovinblastine | 5' Nor anhydrovinblastine | KW 2307 | KW-2307 | KW2307 | Navelbine | Vinorelbine Tartrate |
